Cancer Center Clinical Studies
11 - 17 of 17
Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors
AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia
Larotrectinib RAI Thyroid
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion. The study involves taking a study drug called larotrectinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment).
Cabo/Ifos in Ewing Sarcoma and Osteosarcoma
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib (“the study drug”) to give to patients in combination with a routine chemotherapy drug called ifosfamide.
TAPISTRY
The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts (groups) based on having a specific type of genetic alteration in their tumor. The study includes cohorts for patients whose tumors have genetic alterations in the ROS1, NTRK, PIK3CA, BRAF, or RET genes or a high number of mutations in their tumor.
Pages
- « first
- ‹ previous
- 2
- next ›
- last »